



Press release from Emotra AB (publ)  
Göteborg, 14 December, 2021

## **EMOTRA AB announces the results of the TO 2 subscription-warrant conversion**

Today, 14 December, 2021, Emotra AB (“Emotra” or “the Company”) announced the results of the TO 2 series subscription-warrant conversion. These warrants were emitted in the spring of 2021 in connection with Emotra’s rights issue. During the period 29 November through 13 December, 2021, owners of subscription warrants in the TO 2 series were given the opportunity to convert these warrants into regular stock in Emotra AB. In total, 14,450,356 shares were purchased through the conversion of the same amount of subscription warrants, which equals a conversion rate of approximately 91 percent. This conversion will provide Emotra with a cash injection of approximately 3.8 MSEK before issue expenses.

### **Number of shares and share capital**

This will provide Emotra with approximately 3.8 MSEK before issue expenses, which are estimated to amount to about 0.2 MSEK. When these new shares have been registered at the Swedish Companies Registration Office, the number of outstanding shares in Emotra will increase by 14,450,356, from 82,513,556 to 96,963,912. Also, the Company's share capital will increase by 274,556.76 SEK, from 1,567,757.566 SEK to 1,842,314.33 SEK.

### **For further information about Emotra, please contact:**

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail:  
daniel@emotra.se [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company’s methods/products, NeuraMetrix TC and EDOR<sup>®</sup>, are unique, proprietary and patent-protected.*

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden  
Tel: +46 732-34 41 93, [www.emotra.se](http://www.emotra.se)